MRZM — Marizyme Share Price
0.000.00%
Last trade - 00:00- $6.59m
- $29.14m
- $0.65m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 12.97 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | -3137.7% | ||
| Operating Margin | -5944.65% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | 0.2 | 0.21 | 0.23 | 0.65 | n/a | n/a | 99.98% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Marizyme, Inc. is a medical technology company. The Company is focused on cardiac and surgical care by delivering innovative solutions for coronary artery bypass graft (CABG) surgery and other surgical procedures. Its product DuraGraft, is a one-time intraoperative vascular graft treatment for use in vascular and bypass surgeries that maintains endothelial function and structure, thereby reducing the incidence and complications of graft failure and improving clinical outcomes post bypass surgery. The Company’s product under development includes MATLOC and MAR-FG-001. MATLOC is a lab-on-chip digital screening and diagnostic device platform being developed for quantitative chronic kidney disease (CKD) assessment. The MAR-FG-001 is a tumescent solution base for fat grafting procedures that is used for plastic and cosmetic surgeries in which fat is transferred from one area of the body to another to correct a defect, replace injured tissue, or to make cosmetic enhancements.
Directors
- Vithalbhai Dhaduk CHM (67)
- David Barthel CEO
- George Kovalyov CFO
- Steven Brooks EVP
- Amy Chandler EVP
- Roger Schaller EVP
- Donald Very EVP
- Terry Brostowin DRC (59)
- Stephen Baksa IND (67)
- David Darsch IND (55)
- William Hearl IND
- Julie Kampf IND
- John Moore IND (60)
- Mohammad Shihadah IND (59)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- March 20th, 2007
- Public Since
- April 5th, 1995
- No. of Shareholders
- 401
- No. of Employees
- 11
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 131,793,088
- Address
- 555 HERITAGE DRIVE, SUITE 205, JUPITER, 33458
- Web
- https://marizyme.com/
- Phone
- +1 5619359955
- Auditors
- WithumSmith Brown PC
Upcoming Events for MRZM
Q3 2024 Marizyme Inc Earnings Release
Similar to MRZM
Acorda Therapeutics
Pink Sheets on Nasdaq
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
FAQ
What is the Marizyme share price?
As of Today at 21:56 UTC, shares in Marizyme are trading at $0.05. This share price information is delayed by 15 minutes.
How has the Marizyme share price performed this year?
Shares in Marizyme last closed at $0.05 and the price had moved by -58.38% over the past 365 days. In terms of relative price strength the Marizyme share price has underperformed the S&P500 Index by -65.07% over the past year.
What are the analyst and broker recommendations for Marizyme?
There is no consensus recommendation for this security.
What is the Marizyme dividend yield?
Marizyme does not currently pay a dividend.
Does Marizyme pay a dividend?
Marizyme does not currently pay a dividend.
When does Marizyme next pay dividends?
Marizyme does not currently pay a dividend.
How do I buy Marizyme shares?
To buy shares in Marizyme you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Marizyme?
As of the previous close price of $0.05, shares in Marizyme had a market capitalisation of $7.13m.
Where are Marizyme shares listed?
Here are the trading details for Marizyme:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: MRZM
What kind of share is Marizyme?
Based on an overall assessment of its quality, value and momentum Marizyme is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Marizyme share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the Marizyme share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Marizyme. Over the past six months, its share price has underperformed the S&P500 Index by -67.34%.
As of the last closing price of $0.05, shares in Marizyme were trading -83.25% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Marizyme PE Ratio?
The Marizyme PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.05.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Marizyme?
Marizyme's management team is headed by:
- Vithalbhai Dhaduk - CHM
- David Barthel - CEO
- George Kovalyov - CFO
- Steven Brooks - EVP
- Amy Chandler - EVP
- Roger Schaller - EVP
- Donald Very - EVP
- Terry Brostowin - DRC
- Stephen Baksa - IND
- David Darsch - IND
- William Hearl - IND
- Julie Kampf - IND
- John Moore - IND
- Mohammad Shihadah - IND